LACTUGAL Oral solution Ref.[6400] Active ingredients: Lactulose

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2018  Publisher: Intrapharm Laboratories Ltd, The Courtyard Barns, Choke Lane, Maidenhead, Berkshire SL6 6PT, United Kingdom

Therapeutic indications

Constipation; hepatic encephalopathy (portal systemic encephalopathy).

Posology and method of administration

For oral administration.

The lactulose solution may be administered diluted or undiluted. Each dose may, if necessary, be taken with water or fruit juices etc.

Each dose of lactulose should be swallowed in one and should not be kept in the mouth for an extended period of time.

All dosages should be adjusted to the needs of the individual.

In case of single daily dose, this should be taken at the same time, e.g. during breakfast.

During the therapy with laxatives it is recommended to drink sufficient amounts of fluids (1.5-2 litres, equal to 6-8 glasses) during the day.

Dosing in constipation

Lactulose may be given as a single daily dose or in two divided doses.

After a few days the starting dosage may be adjusted to the maintenance dose based upon treatment response. Several days (2-3 days) of treatment may be needed before treatment effect occurs.

 Starting dose dailyMaintenance dose daily
Adults and adolescents15-45 ml15-30 ml
Children (7-14 years) 15 ml10-15 ml
Children (1-6 years) 5-10 ml5-10 ml
Infants under 1 yearUp to 5 mlUp to 5 ml

Dosing in Hepatic Encephalopathy (for adults only)

Starting dose: 3 to 4 times daily 30-45ml (6-9 × 5ml spoonfuls). This dose may be adjusted to the maintenance dose to achieve two or three soft stools each day.

Paediatric population

The safety and efficacy in children (newborn to 18 years of age) with Hepatic Encephalopathy have not been established. No data are available.

Elderly patients and patients with renal or hepatic insufficiency

No special dosage recommendations exist, since systemic exposure to lactulose is negligible.

Overdose

If the dose is too high, the following may occur: diarrhoea and abdominal pain

Treatment

A dose reduction or cessation of therapy should be considered. Excessive fluid loss due to diarrhoea or vomiting may result in clinically important electrolyte disturbances, and suitable corrective measures should be taken.

There is no specific antidote and supportive, symptomatic treatment should be given.

Shelf life

36 months from the date of manufacture.

Special precautions for storage

Store at a temperature not exceeding 20°C. Do not freeze.

Nature and contents of container

Amber glass winchesters with polypropylene caps as closures: pack sizes 300 ml, 500 ml, 1000 ml and 2000 ml.

Polyethylene containers with polypropylene caps as closures: pack sizes 250 ml, 300 ml, 500 ml, 1000 ml and 2000 ml.

Not all pack sizes may be marketed.

Special precautions for disposal and other handling

There are no special storage or handling instructions for this product.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.